Pharma-Bio Serv (PBSV) FCF Margin (2010 - 2026)
Pharma-Bio Serv's (PBSV) quarterly FCF Margin came in at 13.6% in Q2 2026, down 95.0% on a YoY basis from 272.02% in Q2 2025, and up 20.48% quarter-over-quarter from 17.1% in Q1 2026.
Powered by 
Analysis
Pharma-Bio Serv (PBSV) FCF Margin (2010 - 2026) Analysis & Trends
Pharma-Bio Serv (PBSV) has reported FCF Margin for 16 consecutive years, with 13.6% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, FCF Margin fell 95.0% year-over-year to 13.6%; the trailing twelve-month figure through Apr 2026 stood at 2.7% (up 1271.0% YoY), and the FY2025 full-year result was 2.46%, up 518.0% from the prior year.
- FCF Margin climbed to 13.6% in Q2 2026 per PBSV's latest filing, from 17.1% in the prior quarter.
- Across five years, FCF Margin topped out at 30.47% in Q1 2024 and bottomed at 29.47% in Q2 2024.
- Historically, FCF Margin has averaged 0.48% across 5 years, with a median of 4.43% in 2023.
- The sharpest annual moves came in 2024 and 2025: FCF Margin slumped 4870 bps in 2024, then surged 3974 bps in 2025.
- Over 5 years, FCF Margin stood at 5.35% in 2022, then jumped by 61 bps to 8.62% in 2023, then tumbled by 139 bps to 3.37% in 2024, then soared by 486 bps to 12.99% in 2025, then plunged by 205 bps to 13.6% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 13.6%, 17.1%, and 12.99% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Accenture | 124.62 Bn | 115.58 Bn | 6.13 Bn | 19.23% |
| 2 | UL Solutions | 14.92 Bn | 14.51 Bn | 417.00 Mn | 11.15% |
| 3 | Gartner | 11.76 Bn | 10.28 Bn | 1.19 Bn | 22.58% |
| 4 | Tetra Tech | 9.19 Bn | 8.96 Bn | 243.21 Mn | 17.20% |
| 5 | Booz Allen Hamilton Holding | 8.76 Bn | 8.22 Bn | 1.46 Bn | 8.93% |
| 6 | Genpact | 6.27 Bn | 5.75 Bn | 490.34 Mn | 4.36% |
| 7 | Korn Ferry | 4.28 Bn | 3.15 Bn | 685.99 Mn | 35.39% |
| 8 | Fti Consulting | 4.20 Bn | 4.04 Bn | 316.27 Mn | 14.20% |
| 9 | Grand Canyon Education | 4.01 Bn | 3.73 Bn | 204.08 Mn | 37.08% |
| 10 | Pharma-Bio Serv | 12.37 Mn | 3.89 Mn | 902,041.00 | -13.60% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2026 | -13.60% |
| Jan 31, 2026 | -17.10% |
| Oct 31, 2025 | 12.99% |
| Jul 31, 2025 | 11.94% |
| Apr 30, 2025 | -12.65% |
| Jan 31, 2025 | -17.38% |
| Oct 31, 2024 | -3.37% |
| Jul 31, 2024 | -27.80% |
| Apr 30, 2024 | -29.47% |
| Jan 31, 2024 | 30.47% |
| Oct 31, 2023 | 8.62% |
| Jul 31, 2023 | 20.90% |
| Apr 30, 2023 | -5.50% |
| Jan 31, 2023 | 20.47% |
| Oct 31, 2022 | 5.35% |
| Jul 31, 2022 | 23.12% |
| Apr 30, 2022 | -9.07% |
| Jan 31, 2022 | -6.53% |
| Oct 31, 2021 | 17.17% |
| Jul 31, 2021 | 8.71% |